Gamma-aminobutyric acid (GABA) receptor binding selectively depleted by viral induced granule cell loss in hamster cerebellum

1976 ◽  
Vol 105 (2) ◽  
pp. 365-371 ◽  
Author(s):  
Rabi Simantov ◽  
Mary Lou Oster-Granite ◽  
Robert M. Herndon ◽  
Solomon H. Snyder
2021 ◽  
Vol 28 ◽  
Author(s):  
Pradeep Paudel ◽  
Samir Ross ◽  
Xing-Cong Li

: Novel therapeutic strategies are needed to address depression, a major neurological disorder affecting hundreds of millions of people worldwide. Cannabinoids and their synthetic derivatives have demonstrated numerous neurological activities and may potentially be developed into new treatments for depression. This review highlights cannabinoid (CB) receptors, monoamine oxidase (MAO), N-methyl-D-aspartate (NMDA) receptor, gamma-aminobutyric acid (GABA) receptor, and cholecystokinin (CCK) receptor as key molecular targets of cannabinoids that are associated with depression. The anti-depressant activity of cannabinoids and their binding modes with cannabinoid receptors are discussed, providing insights into rational design and discovery of new cannabinoids or cannabimimetic agents with improved druggable properties.


Sign in / Sign up

Export Citation Format

Share Document